15 Nov 2023
Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P. falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial
This study aimed to assess the safety of a high-dose short-course primaquine treatment (total dose 7 mg/kg over 7 days) in patients with 70% G6PD activity or greater and P falciparum malaria. The trial also aimed to assess the efficicacy of universal radical cure to reduce the risk of subsequent P vivax episodes compared with the current standard treatment for P falciparum, which entails schizontocidal treatment of blood stage parasites plus a single dose of primaquine to eliminate the sexual parasite stages.